Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng Ta Yang, Ross A. Soo, James C.H. Yang, Rasim Gucalp, Balazs Halmos, Angela Märten, Tanja Cufer

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov.

Original languageEnglish (US)
Pages (from-to)2799-2808
Number of pages10
JournalFuture Oncology
Volume16
Issue number34
DOIs
StatePublished - Dec 2020

Keywords

  • EGFR
  • NSCLC
  • afatinib
  • osimertinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study'. Together they form a unique fingerprint.

Cite this